Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade

Jeong, Seong Dong; Jung, Bo‐Kyeong; Ahn, Hyo Min; Lee, Dae Yong; Ha, Jong Hoon; Noh, Ilkoo; Yun, Chae Ok; Kim, Yeu Chun

doi:10.1002/advs.202001308

Cited by 44 publications

(29 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To induce cell death with increased immunogenicity, an ICD inducer is necessary in the first place [19][20][21][22][23][24][25][26][27]. Known therapeutic treatments associated with ICD comprise a variety of cellular stressors, including (but not limited to) conventional chemotherapies (e.g.…”

Section: Main Molecular and Immunological Features Of Icdmentioning

confidence: 99%

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

et al. 2022

View full text Add to dashboard Cite

Immunogenic cell death (ICD) has emerged as a key component of therapy-induced anti-tumor immunity. Over the past few years, ICD was found to play a pivotal role in a wide variety of novel and existing treatment modalities. The clinical application of these techniques in cancer treatment is still in its infancy. Glioblastoma (GBM) is the most lethal primary brain tumor with a dismal prognosis despite maximal therapy. The development of new therapies in this aggressive type of tumors remains highly challenging partially due to the cold tumor immune environment. GBM could therefore benefit from ICD-based therapies stimulating the anti-tumor immune response. In what follows, we will describe the mechanisms behind ICD and the ICD-based (pre)clinical advances in anticancer therapies focusing on GBM.

show abstract

Section: Main Molecular and Immunological Features Of Icdmentioning

confidence: 99%

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, whether the ROS and PTT could trigger ICD, we have investigated DAMPs-related biomarkers. Release of high mobility group box 1 protein (HMGB1), marked overexpression of calreticulin (CRT), secretion of adenosine triphosphate (ATP), and exposure to HSP90 as the characteristic index of DAMPs [31] was assessed by enzyme-linked immunosorbent assay (ELISA). HMGB1 is a highly conserved chromosomal protein that is released from the nucleus in response to mechanical damage and is considered to be the most representative component of DAMPs.…”

Section: Immunogenic Cell Death and Dcs Maturation In Vitromentioning

confidence: 99%

Near‐Infrared II Nanoadjuvant‐Mediated Chemodynamic, Photodynamic, and Photothermal Therapy Combines Immunogenic Cell Death with PD‐L1 Blockade to Enhance Antitumor Immunity

Xiang

Yang

Luo

et al. 2022

Small

View full text Add to dashboard Cite

The efficacy of immune checkpoint inhibition in inducing death of cancer cells is affected by the immunosuppressive “cold” tumor microenvironment, which results in a poor response by the patient's antitumor immune system. However, the immunomodulatory effects of immunogenic cell death in response to irritation by heat energy and reactive oxygen species (ROS) can switch the tumor microenvironment from “cold” to “hot.” This study has developed a nanoadjuvant for immune therapy using iron tungsten oxide (FeWOx)‐based nanosheets with surface PEGylation (FeWOx‐PEG). This FeWOx‐PEG nanoadjuvant serves as a chemodynamic reagent via the Fenton reaction and acts as a photosensitizer for photodynamic and photothermal therapy under near‐infrared II laser irradiation; however, it could also be used to augment tumor‐infiltrating T‐cells and provoke a systemic antitumor immune response by combining the immunogenic cell death triggered by ROS and photothermal therapy with the immune checkpoint blockade. This research demonstrates that application of the FeWOx‐PEG nanoadjuvant under the guidance of magnetic resonance/computed tomography/photoacoustic imaging can eliminate the primary tumor and suppress the growth of distant tumors.

show abstract

“…Other kinds of agents are also under exploration. For example, a fluorinated mitochondria-disrupting helical polypeptides, which could destabilize mitochondrial outer membrane, was developed to over-produce intracellular ROS (iROS), induce ICD and enhance PD-L1 blockade therapy ( Jeong et al, 2021 ).…”

Section: Interlacing Roles Of Ros In Immunotherapymentioning

confidence: 99%

Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword

Wang

Liu

Jiang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are critical mediators in many physiological processes including innate and adaptive immunity, making the modulation of ROS level a powerful strategy to augment anticancer immunity. However, current evidences suggest the necessity of a deeper understanding of their multiple roles, which may vary with their concentration, location and the immune microenvironment they are in. Here, we have reviewed the reported effects of ROS on macrophage polarization, immune checkpoint blocking (ICB) therapy, T cell activation and expansion, as well as the induction of immunogenic cell death. A majority of reports are indicating detrimental effects of ROS, but it is unadvisable to simply scavenge them because of their pleiotropic effects in most occasions (except in T cell activation and expansion where ROS are generally undesirable). Therefore, clinical success will need a clearer illustration of their multi-faced functions, as well as more advanced technologies to tune ROS level with high spatiotemporal control and species-specificity. With such progresses, the efficacy of current immunotherapies will be greatly improved by combining with ROS-targeted therapies.

show abstract

Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade

Cited by 44 publications

References 38 publications

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Near‐Infrared II Nanoadjuvant‐Mediated Chemodynamic, Photodynamic, and Photothermal Therapy Combines Immunogenic Cell Death with PD‐L1 Blockade to Enhance Antitumor Immunity

Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword

Contact Info

Product

Resources

About